The pharmaceutical business is the company’s biggest financial contributor, representing 2/3 of the total turnover of GSK.
The site in Wavre manages the marketing of the GSK products in Belgium and Luxembourg. The principal therapeutic areas of GSK are respiratory disorders, pulmonary arterial hypertension and immunological disorders such as lupus.
Our pharmaceutical business creates value by researching and manufacturing innovative products and making these as widely accessible as possible to countries at all levels of income and development.
40 years of respiratory
Over the past 40 years, we have invested more than any other company in respiratory research. We invented our first asthma treatment in the 1960’s and it remains an important part of our respiratory portfolio. The illustration below provides an overview of this rich history.Error loading Partial View script (file: ~/Views/MacroPartials/InlineImage.cshtml)
Research and collaboration
We also know that we won’t discover everything inside our own labs and that we need to partner with other companies, academic institutions and research charities. This is why GSK has developed successful partnerships with several universities and research centers in Belgium. Find out more about how we are partnering and collaborating in order to drive research.
Find out more about Pharmaceuticals
Our prescription medicines and vaccines
We have treatments for a wide range of conditions as well as more than 40 vaccines worldwide.
BE/COM/0007/15(2) Oct 2017